Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of Pathologic Complete Response for Patients With Breast Cancer Treated With Neratinib in the I-SPY 2 TRIAL.

Purpose In the I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging and Molecular Analysis 2), the pan-erythroblastic oncogene B inhibitor neratinib was available to all hormone receptor (HR)/human epidermal growth factor receptor 2 (HER2) subtypes and graduated in the HR-negative/HER2-positive signature. We hypothesized that neratinib response may be predicted by baseline HER2 epidermal growth factor receptor (EGFR) signaling activation/phosphorylation levels independent of total levels of HER2 or EGFR proteins. Materials and Methods Complete experimental and response data were available for between 130 and 193 patients. In qualifying analyses, which used logistic regression and treatment interaction analysis, 18 protein/phosphoprotein, 10 mRNA, and 12 DNA biomarkers that related to HER family signaling were evaluated. Exploratory analyses used Wilcoxon rank sum and t tests without multiple comparison correction. Results HER pathway DNA biomarkers were either low prevalence or nonpredictive. In expression biomarker analysis, only one gene (STMN1) was specifically associated with response to neratinib in the HER2-negative subset. In qualifying protein/phosphoprotein analyses that used reverse phase protein microarrays, six HER family markers were associated with neratinib response. After analysis was adjusted for HR/HER2 status, EGFR Y1173 (pEGFR) showed a significant biomarker-by-treatment interaction (P = .049). Exploratory analysis of HER family signaling in patients with triple-negative (TN) disease found that activation of EGFR Y1173 (P = .005) and HER2 Y1248 (pHER2) (P = .019) were positively associated with pathologic complete response. Exploratory analysis in this pEGFR/pHER2-activated TN subgroup identified elevated levels of estrogen receptor α (P < .006) in these patients. Conclusion Activation of HER family phosphoproteins associates with response to neratinib, but only EGFR Y1173 and STMN1 appear to add value to the graduating signature. Activation of HER2 and EGFR in TN tumors may identify patients whose diseases respond to neratinib and implies that there is a subset of patients with TN disease who paradoxically exhibit HER family signaling activation and may achieve clinical benefit with neratinib; this concept must be validated in future studies.

[1]  D. Berry,et al.  DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial , 2017, npj Breast Cancer.

[2]  M. Ellis,et al.  Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer , 2017, Clinical Cancer Research.

[3]  M. Berger,et al.  An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer. , 2017, Cancer discovery.

[4]  C. Hatzis,et al.  Co-targeting the HER and IGF/insulin receptor axis in breast cancer, with triple targeting with endocrine therapy for hormone-sensitive disease , 2017, Breast Cancer Research and Treatment.

[5]  M. Dowsett,et al.  Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer , 2017, Breast Cancer Research.

[6]  C. Sotiriou,et al.  RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial , 2017, JAMA oncology.

[7]  R. Bernards,et al.  PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  Giovanni Parmigiani,et al.  Adaptive Randomization of Neratinib in Early Breast Cancer. , 2016, The New England journal of medicine.

[9]  D. Jiang,et al.  Effects of stathmin 1 silencing by siRNA on sensitivity of esophageal cancer cells Eca-109 to paclitaxel. , 2015, Genetics and molecular research : GMR.

[10]  S. Loi,et al.  Precision medicine for metastatic breast cancer—limitations and solutions , 2015, Nature Reviews Clinical Oncology.

[11]  E. Ratner,et al.  Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo , 2015, Molecular Cancer Therapeutics.

[12]  M. Duffy,et al.  Neratinib to inhibit the growth of triple-negative breast cancer cells. , 2015 .

[13]  Donald A Berry,et al.  The Brave New World of clinical cancer research: Adaptive biomarker‐driven trials integrating clinical practice with clinical research , 2015, Molecular oncology.

[14]  J. Baselga,et al.  Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Platt,et al.  Convergent and Divergent Cellular Responses by ErbB4 Isoforms in Mammary Epithelial Cells , 2014, Molecular Cancer Research.

[16]  Jingchun Zhu,et al.  Realizing the Promise of Reverse Phase Protein Arrays for Clinical, Translational, and Basic Research: A Workshop Report , 2014, Molecular & Cellular Proteomics.

[17]  R. West,et al.  Neuregulin autocrine signaling promotes self-renewal of breast tumor-initiating cells by triggering HER2/HER3 activation. , 2014, Cancer research.

[18]  M. Duffy,et al.  Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer , 2013, Oncotarget.

[19]  Martin Clynes,et al.  A gene expression profile indicative of early stage HER2 targeted therapy response , 2013, Molecular Cancer.

[20]  I. Bièche,et al.  Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab , 2013, British Journal of Cancer.

[21]  Li Ding,et al.  Activating HER2 mutations in HER2 gene amplification negative breast cancer. , 2013, Cancer discovery.

[22]  E. Petricoin,et al.  Molecular Analysis of HER2 Signaling in Human Breast Cancer by Functional Protein Pathway Activation Mapping , 2012, Clinical Cancer Research.

[23]  Shuhang Wang,et al.  Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR , 2012, Journal of experimental & clinical cancer research : CR.

[24]  A. Pandiella,et al.  Differential action of small molecule HER kinase inhibitors on receptor heterodimerization: Therapeutic implications , 2012, International journal of cancer.

[25]  D. Berry.  Adaptive clinical trials in oncology , 2012, Nature Reviews Clinical Oncology.

[26]  M. Dowsett,et al.  Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment. , 2011, Endocrine-related cancer.

[27]  E. Perez,et al.  HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  P. Auclair,et al.  Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study , 2009, BMC Cancer.

[29]  D. Berry,et al.  I‐SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy , 2009, Clinical pharmacology and therapeutics.

[30]  A. Laenkholm,et al.  Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors , 2009, Breast Cancer Research.

[31]  Rachel Schiff,et al.  Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. , 2008, Endocrine reviews.

[32]  A. Chaudhuri,et al.  HER2 Status and Benefit from Adjuvant Trastuzumab in Breast Cancer , 2008 .

[33]  M. Ringnér,et al.  Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity , 2007, Proceedings of the National Academy of Sciences.

[34]  D. Márquez,et al.  Epidermal growth factor receptor and tyrosine phosphorylation of estrogen receptor , 2001, Endocrine.

[35]  E. Wight,et al.  Phosphorylation of tyrosine 1248-ERBB2 measured by chemiluminescence-linked immunoassay is an independent predictor of poor prognosis in primary breast cancer patients. , 2006, European journal of cancer.

[36]  J. Attems,et al.  Her‐2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumab‐based therapy in patients with metastatic breast cancer , 2006, International journal of cancer.

[37]  W. Welshons,et al.  Estrogen receptors in membrane lipid rafts and signal transduction in breast cancer , 2006, Molecular and Cellular Endocrinology.

[38]  M. Ellis,et al.  Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  A. Thor,et al.  Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  Christopher J. Barnes,et al.  The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor α to the plasma membrane , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[41]  J. Liao,et al.  Nonnuclear actions of estrogen. , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[42]  Adrian V. Lee,et al.  Cross-talk among estrogen receptor, epidermal growth factor, and insulin-like growth factor signaling in breast cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[43]  D. Márquez,et al.  Membrane-associated binding sites for estrogen contribute to growth regulation of human breast cancer cells , 2001, Oncogene.

[44]  C. Benz,et al.  Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  Sun,et al.  Oestrogen receptor is a critical component required for insulin-like growth factor (IGF)-mediated signalling and growth in MCF-7 cells , 2000, European journal of cancer.

[46]  M. Sliwkowski,et al.  HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. , 1995, Oncogene.